1. Home
  2. PPBT vs RDHL Comparison

PPBT vs RDHL Comparison

Compare PPBT & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PPBT
  • RDHL
  • Stock Information
  • Founded
  • PPBT 2010
  • RDHL 2009
  • Country
  • PPBT Israel
  • RDHL Israel
  • Employees
  • PPBT N/A
  • RDHL N/A
  • Industry
  • PPBT Biotechnology: Pharmaceutical Preparations
  • RDHL Biotechnology: Pharmaceutical Preparations
  • Sector
  • PPBT Health Care
  • RDHL Health Care
  • Exchange
  • PPBT Nasdaq
  • RDHL Nasdaq
  • Market Cap
  • PPBT 5.5M
  • RDHL 3.9M
  • IPO Year
  • PPBT N/A
  • RDHL N/A
  • Fundamental
  • Price
  • PPBT $0.60
  • RDHL $1.61
  • Analyst Decision
  • PPBT Strong Buy
  • RDHL
  • Analyst Count
  • PPBT 1
  • RDHL 0
  • Target Price
  • PPBT $33.00
  • RDHL N/A
  • AVG Volume (30 Days)
  • PPBT 289.8K
  • RDHL 2.9M
  • Earning Date
  • PPBT 11-14-2025
  • RDHL 09-05-2025
  • Dividend Yield
  • PPBT N/A
  • RDHL N/A
  • EPS Growth
  • PPBT N/A
  • RDHL N/A
  • EPS
  • PPBT N/A
  • RDHL N/A
  • Revenue
  • PPBT N/A
  • RDHL $9,550,000.00
  • Revenue This Year
  • PPBT N/A
  • RDHL $381.91
  • Revenue Next Year
  • PPBT N/A
  • RDHL N/A
  • P/E Ratio
  • PPBT N/A
  • RDHL N/A
  • Revenue Growth
  • PPBT N/A
  • RDHL 157.62
  • 52 Week Low
  • PPBT $0.53
  • RDHL $1.06
  • 52 Week High
  • PPBT $13.95
  • RDHL $9.00
  • Technical
  • Relative Strength Index (RSI)
  • PPBT 26.38
  • RDHL 45.55
  • Support Level
  • PPBT $0.56
  • RDHL $1.81
  • Resistance Level
  • PPBT $0.65
  • RDHL $1.97
  • Average True Range (ATR)
  • PPBT 0.03
  • RDHL 0.26
  • MACD
  • PPBT 0.07
  • RDHL -0.06
  • Stochastic Oscillator
  • PPBT 68.66
  • RDHL 4.12

About PPBT Purple Biotech Ltd.

Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.

About RDHL Redhill Biopharma Ltd.

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.

Share on Social Networks: